Earn CME: https://www.naccme.com/program/19-cpc-101-3 This webcast features a presentation by Dr. David Jackman discusses the latest efficacy and safety data, indications, and cost utility of novel therapies into optimal selection and non-small cell lung cancer (NSCLC) pathway placement strategies. © 2019 NACCME, an HMP Company
Strategies for NSCLC: Clinical Pathways in the Era of Biomarker-Driven Care
